Goldman Sachs analyst David Roman initiates coverage on Abbott Laboratories (NYSE:ABT) with a Buy rating and announces Price Target of $121.
Goldman Sachs Initiates Coverage On Abbott Laboratories With Buy Rating, Announces Price Target of $121
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.